Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study
| Autor: | Jordan C. Pruce, Jessica R. Allegretti, Rahul S. Dalal, Jenna Marcus, Scott Esckilsen, Edward L. Barnes |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Hepatology medicine.diagnostic_test business.industry Remission Induction Gastroenterology Disease medicine.disease Ulcerative colitis Inflammatory bowel disease Cohort Studies Treatment Outcome Crohn Disease Therapeutic drug monitoring Internal medicine Ustekinumab Humans Medicine Colitis Ulcerative Dose intensification Dosing business Cohort study medicine.drug |
| Zdroj: | Clinical Gastroenterology and Hepatology. 20:2399-2401.e4 |
| ISSN: | 1542-3565 |
| DOI: | 10.1016/j.cgh.2021.03.028 |
| Popis: | Ustekinumab has been shown to be effective for the treatment of ulcerative colitis (UC); however, >40% of patients have suboptimal clinical response after induction and maintenance dosing every 8 weeks.1,2 The best management approach for these patients is unclear. Many undergo empiric dose intensification to every 4 weeks or every 6 weeks, a nonstandardized decision because of limited data supporting therapeutic drug monitoring of ustekinumab.3 In Crohn's disease, approximately 50% of patients undergo ustekinumab dose intensification, which seems to be effective based on prior work from our group and others.4-8 However, similar data in UC are lacking. In this real-world multicenter cohort study, we sought to identify predictors and outcomes of ustekinumab dose intensification in UC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|